Viking, NASH

Viking, NASH

Title: A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)

Associated condition: NASH

Status: Currently enrolling

Brief summary: This is a double-blind, placebo-controlled, randomized Phase 2 study in 337 subjects with biopsy-proven nonalcoholic steatohepatitis (NASH) and fibrosis.

Subjects will be randomized into five treatment arms with an equal distribution of men and women in each treatment arm. Subjects in each of the experimental arms will receive 1.0 mg VK2809, 2.5 mg VK2809, 5.0 mg VK2809, or 10.0 mg VK2809 in capsule form. Subjects in the placebo comparator group will receive matching placebos. Following 52 weeks of administration, subjects will undergo a 4-week off-drug phase.

Primary objectives: To assess the efficacy, safety, and tolerability of 52-week course of VK2809 followed by a 4-week off-drug phase in subjects with biopsy-proven NASH with fibrosis.

Estimated length of study: Primary outcome measures have an estimated time frame of 12 weeks with an estimated completion date of March 2021, while the time frame for secondary outcome measures is 52 weeks, with an estimated completion date of November 2021.

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

HIPAA COMPLIANT FORM

Title: A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)

Associated condition: NASH

Status: Currently enrolling

Brief summary: This is a double-blind, placebo-controlled, randomized Phase 2 study in 337 subjects with biopsy-proven nonalcoholic steatohepatitis (NASH) and fibrosis.

Subjects will be randomized into five treatment arms with an equal distribution of men and women in each treatment arm. Subjects in each of the experimental arms will receive 1.0 mg VK2809, 2.5 mg VK2809, 5.0 mg VK2809, or 10.0 mg VK2809 in capsule form. Subjects in the placebo comparator group will receive matching placebos. Following 52 weeks of administration, subjects will undergo a 4-week off-drug phase.

Primary objectives: To assess the efficacy, safety, and tolerability of 52-week course of VK2809 followed by a 4-week off-drug phase in subjects with biopsy-proven NASH with fibrosis.

Estimated length of study: Primary outcome measures have an estimated time frame of 12 weeks with an estimated completion date of March 2021, while the time frame for secondary outcome measures is 52 weeks, with an estimated completion date of November 2021.

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.